年轻成人急性髓系白血病的分子监测对比标准临床照护:英国NCRI AML17和AML19随机对照3期试验结果
在AML17和AML19两项3期试验中,637例16-60岁初诊急性髓系白血病且有可监测分子标志物的患者按2:1随机分配至序贯分子MRD监测组或仅标准临床照护组。中位随访4.9年,3年总生存率监测组70% vs 无监测组73%,Meta分析HR 1.11(95%CI 0.83-1.49;p=0.25)。预设亚组中NPM1合并FLT3-ITD突变患者监测组3年总生存69% vs 无监测组58%(HR 0.53,95%CI 0.31-0.91;p=0.021)。
要点
- 总体人群分子MRD监测未改善总生存:3年OS 70% vs 73%,HR 1.11(95%CI 0.83-1.49;p=0.25)。
- NPM1合并FLT3-ITD亚组监测组3年OS 69% vs 无监测组58%,HR 0.53(95%CI 0.31-0.91;p=0.021)。
- NPM1无FLT3-ITD及融合基因转录本亚组未见生存差异。
核心结论
- 序贯分子MRD监测联合MRD指导治疗未改善整个研究人群的总生存。
- 在基线NPM1合并FLT3-ITD突变亚组中,观察到MRD监测的生存获益。
研究设计与样本
- 英国NCRI AML17和AML19随机对照3期试验,在英国、丹麦和新西兰进行。
- 筛查16-60岁初诊急性髓系白血病患者中适合疾病监测的分子标志物,包括NPM1突变和融合基因。
- 有标志物患者按2:1随机分配至序贯分子MRD监测组(治疗期间及治疗后3年)或仅标准临床照护无分子监测组。
- AML17入组1836例(2012年6月1日至2014年12月31日),AML19入组965例(2015年11月9日至2018年1月23日),两试验共637例随机分配(AML17监测组289例、无监测组144例;AML19监测组136例、无监测组68例)。
主要发现
- 中位随访4.9年(IQR 3.6-5.9),3年总生存率监测组70%(95%CI 66-75)vs 无监测组73%(95%CI 68-80)。
- 两研究Meta分析显示总生存无差异(HR 1.11,95%CI 0.83-1.49;p=0.25)。
- NPM1合并FLT3-ITD突变患者3年总生存率监测组69%(95%CI 60-79)vs 无监测组58%(95%CI 45-74)(HR 0.53,95%CI 0.31-0.91;p=0.021)。
- NPM1突变无FLT3-ITD患者3年总生存率监测组69%(95%CI 62-77)vs 无监测组78%(95%CI 70-87)(HR 1.56,95%CI 0.96-2.52)。
- 融合基因转录本患者3年总生存率监测组72%(95%CI 65-79)vs 无监测组77%(95%CI 68-87)(HR 1.28,95%CI 0.80-2.18)。
关键数值与推荐
- 主要终点为总生存。
- 预设亚组分析按分子组进行:NPM1mut合并FLT3-ITD、NPM1mut无FLT3-ITD、融合基因转录本。
- 监测组中,治疗医生决定是否及如何将MRD结果纳入患者治疗,包括MRD复发情况。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with acute myeloid leukaemia treated with curative intent, the detection of measurable residual disease (MRD) generally confers a poor prognosis. This study aimed to identify whether altering treatment based on MRD results can improve survival. METHODS: In the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials, performed in the UK, Denmark, and New Zealand, we screened patients aged 16-60 years with newly diagnosed acute myeloid leukaemia for molecular markers suitable for disease monitoring, including NPM1 mutations and fusion genes. Patients with a marker were randomly assigned (2:1) to either sequential molecular MRD monitoring during treatment and for 3 years after, or standard clinical care only with no molecular monitoring. In the monitoring group, treating physicians decided whether and how to incorporate the MRD results into the patient's therapy, including in cases of MRD relapse. The primary endpoint was overall survival. Prespecified subgroup analysis of the primary outcome included analysis by molecular group (NPM1mut with FLT3-ITD, NPM1mut without FLT3-ITD, and fusion gene transcripts). Both trials were registered with ISRCTN, ISRCTN55675535 and ISRCTN78449203, and are completed. FINDINGS: In the AML17 trial, 1836 patients were enrolled between June 1, 2012 and Dec 31, 2014. In the AML19 trial, 965 patients were enrolled between Nov 9, 2015, and Jan 23, 2018. 637 patients were randomly assigned across both trials (289 to MRD monitoring and 144 to no monitoring in AML17 and 136 to MRD monitoring and 68 to no monitoring in AML19). With a median follow-up time of 4·9 years (IQR 3·6-5·9), overall survival at 3 years was 70% (95% CI 66-75) in patients in the monitoring group and 73% (68-80) in patients in the no-monitoring group. Meta analysis of the two studies showed no difference in overall survival (hazard ratio [HR] 1·11, 95% CI 0·83-1·49; p=0·25). In the pre-specified subgroup analysis of the primary endpoint, overall survival at 3 years in patients with both NPM1 and FLT3 internal tandem duplication (ITD) mutations was 69% (95% CI 60-79) in the monitoring group and 58% (45-74) in the no-monitoring group (HR 0·53, 95% CI 0·31-0·91; p=0·021). However there was no difference in survival by randomisation in patients with NPM1 mutations without FLT3-ITD (overall survial 69% [95% CI 62-77] in the monitoring group and 78% [70-87] in the no monitoring group; HR 1·56, 95% CI 0·96-2·52) or those with fusion gene transcripts (overall survial 72% [95% CI 65-79] in the monitoring group and 77% [68-87] in the no monitoring group; HR 1·28, 95% CI 0·80-2·18). INTERPRETATION: Sequential molecular MRD monitoring, coupled with MRD-guided treatment, did not improve overall survival in the entire study population; however, in the subgroup of patients with baseline NPM1 and FLT3 ITD mutations, we observed a survival benefit for MRD monitoring. FUNDING: National Institute for Health Research, Blood Cancer UK, and Cancer Research UK.
引用
- Potter N, Jovanovic J, Ivey A, et al. Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials. Lancet Haematol. 2025. PMID: 40306832. doi:10.1016/S2352-3026(25)00037-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。